SINGAPORE, November 02, 2022 (GLOBE NEWSWIRE) – Tessa Therapeutics Ltd., a clinical-stage cell therapy company focused on developing innovative cancer treatments for hematological malignancies and solid tumors, has announced that Thomas Willemsen, President and CEO, along with Dr. Ivan D. Horak, Chief Medical Officer and Chief Scientific Officer, will present at the Stifel Healthcare Conference 2022. This event will be held on November 15-16, 2022, at the Lotte New York Palace Hotel in New York City.

Presentation Schedule:

Event: Stifel Healthcare Conference 2022
Date: Tuesday, November 15, 2022
Time: 8:00 – 8:30 a.m. ET
Location: Lotte New York Palace Hotel, New York, NY
During the conference, Mr. Willemsen, Dr. Horak, and Wilson W. Cheung, Chief Financial Officer, will engage in one-on-one meetings with registered investors to discuss Tessa’s business and clinical development strategies, recent achievements, and future milestones.

About Tessa Therapeutics

Tessa Therapeutics is at the forefront of developing next-generation cell therapies aimed at treating hematological cancers and solid tumors. Its leading clinical candidate, TT11, is an autologous CD30-CAR-T therapy currently in investigation for relapsed or refractory classical Hodgkin lymphoma, both as a monotherapy (Phase 2) and in combination therapies (Phase 1b). TT11 has received RMAT designation from the FDA and has access to the PRIME scheme by the European Medicines Agency. Additionally, Tessa is advancing an allogeneic “off-the-shelf” cell therapy platform targeting various cancers, which utilizes Epstein Barr Virus Specific T Cells (EBVSTs) augmented with CD30-CAR. A therapy utilizing this platform is presently undergoing a Phase 1 clinical trial in CD30-positive lymphomas. Tessa is headquartered in Singapore, where it has established a state-of-the-art commercial cell therapy manufacturing facility. For more information, visit www.tessacell.com.

Cautionary Note on Forward-Looking Statements

This press release includes forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995. Such statements may include terms like “anticipate,” “estimate,” “expect,” “project,” “intend,” and similar expressions. These forward-looking statements reflect management’s current expectations and beliefs and are subject to various risks and uncertainties that may cause actual results to differ materially. Factors that could affect these outcomes include the company’s financial results, ability to raise capital, reliance on strategic partnerships, the applicability of patents, timing for clinical trials, and competition from other biopharmaceutical companies. The company advises against undue reliance on any forward-looking statements made herein, which reflect views only as of the date they were issued and disclaims any obligation to update or revise these statements in light of future developments.